Roche publishes results from Evrysdi trial program

25 February 2021

Detailed results from the FIREFISH study of Roche’s (ROG: SIX) Evrysdi (risdiplam) have been published in the New England Journal of Medicine.

Data from the trial were used to support approval in the USA for infants with symptomatic Type 1 spinal muscular atrophy (SMA), with the FDA delivering its verdict in August 2020.

The 12-month data from the trial show Evrysdi helped 90% of the infants survive without permanent ventilation and 33% to sit without support for at least five seconds.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK